1Ciarmela P, Boschi S, Bloise E, et al. Polymorphisms of FAS and FAS ligand genes in preeclamptic women [ J ]. Eur J Obstet Gynecol Reprod Biol, 2010, 148 (2) : 144- 146.
2Bourque DK, Avila L, Penaherrera M, et al. Decreased pla- cental methylation at the H19/IGF2 imprinting control re- gion is associated with normotensive intrauterine growth restriction but not preeclampsia [ J ]. Placenta, 2010, 31 (3) : 197-202.
3Bdolah Y, Lam C, Rajakumar A, et al. Twin pregnancy and the risk of preeclampsia:bigger placenta or relative ische- mia? [ J ]. Am J Obstet Gynecol, 2008,198 (4) : 428. el- 428. e6.
4Maynard SE, Moore Simas TA, Solitro M J, et al. Circulat- ing angiogenic factors in singleton vs multiple-gestation pregnancies [ J ]. Am J Obstet Gynecol, 2008,198 (2) : 200. el-200, e7.
5Bdolah Y, Palomaki GE, Yaron Y, et al. Circulating angio- genic proteins in trisomy 13 [ J ]. Am J Obstet Gynecol, 2006,194( 1 ) :239-2,45.
6Levine R J, Lam C, Qian C, et al. Soluble endoglin and oth- er circulating antiangiogenic factors in preeclampsia[ J ]. N Engl J Med,2006,355 (10) :992-1005.
7Kim SY, Ryu HM, Yang JH, et al. Increased sFlt-1 to P1- GF ratio in women who subsequently develop preeclampsia [ J]. J Korean Med Sci ,2007,22(5 ) :a73-a77.
8Masuyama H, Nakatsukasa H, Takamoto N, et al. Correla- tion between soluble endoglin, vascular endothelial growth factor receptor-l, and adipocytokines in p reeclamp sia [ J ]. J Clin Endocrinol Metab, 2007,92 (7) : 2672-2679.
9Levine R J, Lam C, Qian C, et al. Soluble endoglin and oth- er circulating antiangiogenic factors in preeclampsia [ J ]. N Engl J Med,2006,355 (10) :992-1005.
10Holston AM, Qian C, Yu KF, et al. Circulating angiogenic factors in gestational proteinuria without hypertension [ J ]. Am J Obstet Gynecol, 2009,200 (4) : 392. e1-392. e10.
2Iversen AC, Nyugen OT,Tommerdal LF,et al. The HLA-G 14 bp gene polynmrphism and decidual HLA-G 14 bp gene expression in pre-eclamptic and normal pregnancies. J Reprod Immunol, 2008, 78:158-165.
3Blidarn I,Cianga C,Slatineanu SJ-M. NK ceils in the physiology of the fetomaternal relationships. Rev Med Chir Soc Med Nat Iasi, 2001,105 : 19-22.
4Le Bouteiller P,Legrand-Abravanel F,Solier C. Soluble HLA-G1 at the materno-fetal interface-a review. Placenta, 2003,24 ( Suppl A) :S10-15.
5Kanai T, Fujii T, Unno N, et al. Human leukocyte antigen-G- expressing cells differently modulate the release of cytokines from mononuclear cells present in the decidua versus peripheral blood. Am J Reprod Immunol, 2001,45:94-99.
6Tan CY, Ho JF, Chong YS, et al. Paternal contribution of HLA- G significantly increases risk for pre-eclampsia in multigravid pregnancies. Mol Hum Reprod, 2008, 14:317-324.
7Yie SM, Li LH, Li YM, et al. HLA-G protein concentrations in maternal serum and placental tissue are decreased in pre- eclampsia. Am J Obstet Gynecol, 2004, 91:525-529.
8Hviid TV. HLA-G in human reproduction: aspects of geneticsfunction and pregnancy complications. Hum Reprod Update,2006, 12:209-232.
9Rizzo R, Andersen AS, Lassen MR, et al. Soluble human leukocyte antigen-G isoforms in early and late pregnancy. Am J Reprod Immuno1,2009 ,62 :320-338.
10Tan CY, Chong YS, Loganath A, et al. Possible gene-gene interaction of KIR2DL4 with its cognate ligand HLA-G in modulating risk for preeclampsia. Repord Sci, 2009, 16: 1135- 1143.
8Catov JM, Ness RB, Kip KE, et al. Risk of early or severe preeclampsia related to preexisting conditions. Int J Epidemi ol, 2007, 36: 412-419.
9Bettina Toth,Udo Jeschke,Nina Rogenhofer,Christoph Scholz,Wolfgang Würfel,Christian J. Thaler,Antonis Makrigiannakis.Recurrent miscarriage: current concepts in diagnosis and treatment[J]Journal of Reproductive Immunology,2010(1).
10Shigeru Saito,Arihiro Shiozaki,Akitoshi Nakashima,Masatoshi Sakai,Yasushi Sasaki.The role of the immune system in preeclampsia[J]Molecular Aspects of Medicine,2007(2).
